Maxim Group Upgrades AIM ImmunoTech (AIM) to Buy
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy upgraded AIM ImmunoTech (NYSE: AIM) from Hold to Buy with a price target of $2.00.Management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
